Emergent BioSolutions, Inc. (EBS)
5.89
-0.15
(-2.48%)
USD |
NYSE |
Nov 12, 16:00
5.885
0.00 (0.00%)
Pre-Market: 20:00
Emergent BioSolutions Net Income (Quarterly) : -32.70M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -32.70M |
| June 30, 2026 | -180.20M |
| March 31, 2026 | 6.80M |
| December 31, 2025 | -54.60M |
| September 30, 2025 | 51.20M |
| June 30, 2025 | -12.00M |
| March 31, 2025 | 68.00M |
| December 31, 2024 | -31.30M |
| September 30, 2024 | 114.80M |
| June 30, 2024 | -283.10M |
| March 31, 2024 | 9.00M |
| December 31, 2023 | -49.50M |
| September 30, 2023 | -263.40M |
| June 30, 2023 | -261.30M |
| March 31, 2023 | -186.20M |
| December 31, 2022 | -88.00M |
| September 30, 2022 | -87.10M |
| June 30, 2022 | -56.40M |
| March 31, 2022 | -3.70M |
| December 31, 2021 | 189.30M |
| September 30, 2021 | -32.70M |
| June 30, 2021 | 4.60M |
| March 31, 2021 | 69.70M |
| December 31, 2020 | 185.40M |
| September 30, 2020 | 39.50M |
| Date | Value |
|---|---|
| June 30, 2020 | 92.70M |
| March 31, 2020 | -12.50M |
| December 31, 2019 | 46.90M |
| September 30, 2019 | 43.20M |
| June 30, 2019 | -9.50M |
| March 31, 2019 | -26.00M |
| December 31, 2018 | -3.40M |
| September 30, 2018 | 20.94M |
| June 30, 2018 | 50.14M |
| March 31, 2018 | -4.908M |
| December 31, 2017 | 33.94M |
| September 30, 2017 | 33.55M |
| June 30, 2017 | 4.616M |
| March 31, 2017 | 10.48M |
| December 31, 2016 | 32.29M |
| September 30, 2016 | 20.39M |
| June 30, 2016 | -2.042M |
| March 31, 2016 | 11.89M |
| December 31, 2015 | 42.49M |
| September 30, 2015 | 42.09M |
| June 30, 2015 | 14.10M |
| March 31, 2015 | -21.52M |
| December 31, 2014 | 30.12M |
| September 30, 2014 | 21.83M |
| June 30, 2014 | 5.029M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 653.60M |
| Arcturus Therapeutics Holdings, Inc. | -7.414M |
| Capricor Therapeutics, Inc. | -42.66M |
| Travere Therapeutics, Inc. | -61.04M |
| Syndax Pharmaceuticals, Inc. | -49.43M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 110.00M |
| Total Expenses (Quarterly) | 142.70M |
| EPS Diluted (Quarterly) | -0.6374 |
| Enterprise Value | 638.96M |
| Gross Profit Margin (Quarterly) | 18.09% |
| Profit Margin (Quarterly) | -29.73% |
| Earnings Yield | -86.54% |
| Operating Earnings Yield | 10.29% |
| Normalized Earnings Yield | -34.29 |